386O Exploratory biomarker analysis of DESTINY-CRC01, a phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd, DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC)
暂无分享,去创建一个
T. Yoshino | I. Chau | K. Inaki | Kazuhiko Kobayashi | T. Nishina | K. Yamaguchi | J. Rodriguez | K. Raghav | H. Kawakami | M. Bartolomeo | M. Koga | T. Masuishi | A. Grothey | Y. Kuwahara | E. Élez | S. Siena | F. Suto | I. Takehara